Deal complements Emergent’s development of vaccines and therapeutics.
Expanded strategic deal includes equipment and co-commercialization.
R&D project will expand Shenzhen Hepalink’s product line and diversification efforts.
Doubles revenues, records a profit of $800,000
NantPro will manufacture plasma-derived product for US market.
PrioClear prion capture resin is used in plasma product production.